Skip to main content
. 2018 Aug 14;9:1806. doi: 10.3389/fmicb.2018.01806

Table 1.

Clinical, histologic, viral, and genetic features of the seven patients and 45 lesions analyzed.

Pt Sex/age (years) Lesion code Weeks on BRAFi1 (weeks) Body site SE/NSE2 Diagnosis3 Viral features4 Mutations5 Beta-PV6 Alpha-PV Gamma-PV IHC7 HPyV68 HPyV78 HPyV98 TSPyV8 MCPyV8
1 M/67 V1 9 Scalp SE VW Y NOTCH1, CREBBP 8, 9, 36, 38, 111 28 ND 7.5 × 10−6 3.6 × 10−2 Neg Neg 1.7 × 10−2
V2 9 Suprapubic NSE V K Y NOTCH1, HRAS, CARD11 8, 24, 36, 92, 111 ND ND ND ND ND ND
V3 9 Post-auricular SE VW Y TGFBR2, CDKN2a, CARD11, NOTCH2, CREBBP 8, 36 ND ND ND ND ND ND
V4 9 Arm SE SCC Y TGFBR1, NOTCH1, HRAS 8, 12, 24, 36, 111, FA51 ND Neg 1.7 × 10−4 Neg Neg 4.6 × 10−2
V5 9 Inner Thigh NSE VW Y NOTCH1, NOTCH2, HRAS, CREBBP 8, 12, 36, 111 ND 2.9 × 10−4 Neg Neg Neg 2.8 × 10−2
V6 9 Lower Back NSE SCC Y TP53, HRAS 12, 36, 92 ND 5.12 × 10−5 1.3 × 10−1 Neg Neg 3.9 × 10−3
V7 9 Shoulder NSE SCC Y NOTCH1, TP53, TGFBR1, CREBBP 15, 24, 36, 76, 92, 107, FA84 Neg Neg 3.9 × 10−5 Neg Neg 1.8 × 10−2
V8 9 Posterior neck SE VK Y NOTCH1, CARD11, TGFBR1 8, 24, 36, 93 Neg 4.6 × 10−5 4.8 × 10−4 Neg Neg 2.3 × 10−1
V9 9 Cheek SE VW Y HRAS, TP53∗, NOTCH1,∗ NOTCH2∗ 8, 12, 24, 36, 76, 92 93 28 ND ND ND ND ND ND
V11 13 Scalp SE VW Y NOTCH1, TGFBR2, CARD11, CREBBP 8,23, 36, 92, 93 Neg Neg 2.2 × 10−4 Neg Neg 1 × 10−1
V12 13 Abdomen NSE N-NSE N NOTCH1 5, 92 ND ND ND ND ND ND
V13 13 Lower back NSE SCC Y Nil 8, 24, 92, 107, 111, FA14 Neg 3.9 × 10−5 2.4 × 10−4 Neg Neg 5.9 × 10−3
V14 13 Popliteal Fossa NSE VW Y NOTCH1, CREBBP 12, 24, 36 ND Neg 1.3 × 10−2 Neg Neg 1.7 × 10−3
V15 13 Post-auricular SE VW Y CARD11 93 ND Neg 1.6 × 10−3 Neg Neg 5.6 × 10−2
V16 13 Abdomen NSE VW Y TP53, HRAS 8, 36, 92, 93 ND Neg 6, × 10−4 Neg Neg 9.9 × 10−3
V17 13 Abdomen NSE VW Y NOTCH1, CDKN2a 8, 36, 92, 113 ND Neg 1.4 × 10−1 Neg Neg 6.2 × 10−4
V18 14 Chest NSE VW Y NOTCH1, HRAS, KRAS 8∗∗, 12, 24, 76, 92∗∗, 111 Neg 1.12 × 10−5 5, × 10−5 Neg Neg 5.8 × 10−3
V19 14 Groin NSE SCC Y HRAS, NOTCH1 8, 12, 24, 36, 92 Neg 3.93 × 10−6 1.4 × 10−4 Neg Neg 3.6 × 10−3
V20 14 Chest SE SCC Y Nil 8, 12, 24, 92∗∗, 93 Neg 1.29 × 10−5 2.4 × 10−4 Neg Neg 1.2 × 10−2
V25 18 Arm SE N-P V27 N NOTCH1 Neg ND ND ND ND ND ND
V26 18 Abdomen NSE VW Y CARD11, NOTCH1, HRAS, CREBBP 8, 92 Neg Neg 5.9 × 10−5 Neg Neg 5.3 × 10−3
V27 18 Upper arm SE SCC Y HRAS, CARD11, CREBBP, NOTCH1 NOTCH2∗ KRAS∗ TP53∗ Novel Neg Neg Neg Neg Neg Neg
V28 18 Lower abdomen NSE SCC Y NOTCH2, NOTCH1∗ Neg Neg ND ND ND ND ND
V31 34 Cheek SE VK N Nil Novel ND 3.66 × 10−6 2.4 × 10−4 Neg Neg 7.6 × 10−3
V32 34 Upper Arm SE VW Y NOTCH1, NOTCH2, HRAS, CREBBP, TP53∗ 24∗∗, 36, 92, 93 ND ND ND ND ND ND
2 M/35 V10 13 Chin SE VW Y Nil 8, 12, 80∗∗, 76 57∗∗ 57, beta ND ND ND ND ND
V29 28 Scapula NSE VW Y NOTCH2, CREBBP 12∗∗, 8, 20, 23, 36,76, 80, 92, 96 57 ND ND D ND ND ND
3 M/56 V21 8 Neck SE VK N HRAS, CARD11, NOTCH1 ∗ NOTCH2∗ 22, 115, 150 ND 3.73 × 10−5 6.4 × 10−5 Neg Neg Neg
V22 14 Post-auricular SE VW Y TGFBR1, HRAS NOTCH2∗ 22, 107 ND ND ND ND ND ND
V23 14 Upper arm SE SCC Y CREBBP, CARD11, TGFBR1, NOTCH2∗ 2, 14D, 22, 38, 107, 115 Neg Neg Neg Neg Neg 1.3 × 10−4
V24 14 Upper Arm SE N-P to V23 N NOTCH1 Novel ND ND ND ND ND ND
4 F/33 V30 16 Abdomen NSE SCC N TP53, HRAS, NOTCH1∗ NOTCH2∗ Neg FA49 ND Neg Neg Neg Neg Neg
5 M/87 V33 6 Ear SE VW Y NOTCH1, TP53 9 ND Neg Neg Neg Neg Neg
V34 6 Chin SE AK Y Nil 9, 38 ND Neg 1.5 × 10−5 Neg Neg Neg
6 F/82 V35 12 Neck SE SCC Y TGFBR1, TGFBR2, NOTCH1, TP53, KRAS, NOTCH2, CARD11, CREBBP Neg ND Neg Neg Neg Neg Neg
V36 12 Neck SE N-P V35 N Nil Neg ND ND ND ND ND ND
V37 12 Neck SE N -SE N NOTCH1, CARD11 Neg ND ND ND ND ND ND
V38 12 Shoulder NSE VW Y TGFBR1, TGFBR2, TP53, KRAS, NRAS, CARD11, CREBBP Neg ND ND ND ND ND ND
V39 12 Lower Leg SE SP Y TGFBR1, NOTCH1, NOTCH2,, TP53, CREBBP Neg ND Neg Neg Neg Neg 1.5 × 10−3
V40 12 Arm SE SCC Y TGFBR2, CREBBP Neg ND Neg Neg 4 × 10−4 Neg 2.9 × 10−3
7 F/54 V41 11.5 Neck SE N-SE N NOTCH2, CREBBP Novel ND ND ND ND ND ND
V42 11.5 Back NSE VW Y TP53 80 ND Neg Neg Neg Neg Neg
V43 11.5 Back NSE M NOTCH1, NOTCH2, NRAS, CARD11, CREBBP 80 ND Neg Neg Neg Neg 9 × 10−4
V44 11.5 Back NSE VW Y CARD11 80∗∗ ND Neg Neg Neg Neg Neg
V45 11.5 Back NSE AK Y NOTCH1, TP53 80 ND Neg Neg Neg Neg 1.4 × 10−4

1Weeks on BRAFi: number of weeks on vemurafenib at the time lesion was removed. 2SE/NSE: Sun exposed or non-sun exposed body site. 3Diagnosis: SCC – well differentiated SCC; V, viral wart; VK, verrucous keratosis; AK, actinic keratosis; N-P, normal skin perilesional to; N-SE, normal skin sun exposed; N-NSE – normal skin non sun exposed; M, benign melanocytic; SP, squamoproliferative lesion with viral features and dysplasia but no clear evidence of invasion. 4Viral features: Y, yes; N, no: yes if koilocytosis was observed in conjunction with at least 3 of the following 5 features: acanthosis, hypergranulosis, parakeratosis, hyperkeratosis and typical papillomatous architecture. 5Mutations: these have previously been published (South, 2014; Cammareri, 2016). ∗ indicates lesion bisected and results represent total mutations found across both portions. 6Beta-PV: beta HPV types. Beta-PV types associated with strong bands on the RH assay are recorded as ∗∗; neg, negative. 7 IHC; immunohistochemistry – performed on 12 selected lesions. 8HPyV6, -7, -9, TSPyV and MCPyV: neg, negative; N/D, not done; values recorded are viral copies per cell.